<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ep-patent-document PUBLIC "-//EPO//EP PATENT DOCUMENT 1.5//EN" "ep-patent-document-v1-5.dtd">
<ep-patent-document id="EP12731507B8W1" file="EP12731507W1B8.xml" lang="en" country="EP" doc-number="2729496" kind="B8" correction-code="W1" date-publ="20171018" status="c" dtd-version="ep-patent-document-v1-5">
<SDOBI lang="en"><B000><eptags><B001EP>ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSKBAHRIS..MTNORSMESM..................</B001EP><B003EP>*</B003EP><B005EP>J</B005EP><B007EP>BDM Ver 0.1.63 (23 May 2017) -  2999001/0</B007EP></eptags></B000><B100><B110>2729496</B110><B120><B121>CORRECTED EUROPEAN PATENT SPECIFICATION</B121></B120><B130>B8</B130><B132EP>B1</B132EP><B140><date>20171018</date></B140><B150><B151>W1</B151><B153>73</B153><B155><B1551>de</B1551><B1552>Bibliographie</B1552><B1551>en</B1551><B1552>Bibliography</B1552><B1551>fr</B1551><B1552>Bibliographie</B1552></B155></B150><B190>EP</B190></B100><B200><B210>12731507.5</B210><B220><date>20120706</date></B220><B240><B241><date>20140131</date></B241><B242><date>20150615</date></B242></B240><B250>en</B250><B251EP>en</B251EP><B260>en</B260></B200><B300><B310>201161504987 P</B310><B320><date>20110706</date></B320><B330><ctry>US</ctry></B330><B310>201100518</B310><B320><date>20110706</date></B320><B330><ctry>DK</ctry></B330></B300><B400><B405><date>20171018</date><bnum>201742</bnum></B405><B430><date>20140514</date><bnum>201420</bnum></B430><B450><date>20170913</date><bnum>201737</bnum></B450><B452EP><date>20170330</date></B452EP><B480><date>20171018</date><bnum>201742</bnum></B480></B400><B500><B510EP><classification-ipcr sequence="1"><text>C07K  16/00        20060101AFI20130129BHEP        </text></classification-ipcr></B510EP><B540><B541>de</B541><B542>MODULATION EINER KOMPLEMENTABHÄNGIGEN-ZYTOTOXIZITÄT DURCH MODIFIKATION DES C-TERMINUS SCHWERER ANTIKÖRPERKETTEN</B542><B541>en</B541><B542>MODULATION OF COMPLEMENT-DEPENDENT CYTOTOXICITY THROUGH MODIFICATIONS OF THE C-TERMINUS OF ANTIBODY HEAVY CHAINS</B542><B541>fr</B541><B542>MODULATION DE LA CYTOTOXICITÉ DÉPENDANTE DU COMPLÉMENT PAR DES MODIFICATIONS DE L'EXTRÉMITÉ C-TERMINALE DES CHAÎNES LOURDES D'ANTICORPS</B542></B540><B560><B561><text>WO-A2-2007/087420</text></B561><B561><text>WO-A2-2007/106707</text></B561><B561><text>WO-A2-2008/006554</text></B561><B561><text>US-A1- 2010 297 697</text></B561><B562><text>HARRIS R J ET AL: "Identification of multiple sources of charge heterogeneity in a recombinant antibody.", JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS 10 MAR 2001 LNKD- PUBMED:11270864, vol. 752, no. 2, 10 March 2001 (2001-03-10), pages 233-245, XP002682609, ISSN: 1387-2273</text></B562><B562><text>LINTAO WANG ET AL: "Structural Characterization of a Recombinant Monoclonal Antibody by Electrospray Time-of-Flight Mass Spectrometry", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 22, no. 8, 1 August 2005 (2005-08-01) , pages 1338-1349, XP019370906, ISSN: 1573-904X, DOI: 10.1007/S11095-005-5267-7</text></B562><B562><text>STROHL ET AL: "Optimization of Fc-mediated effector functions of monoclonal antibodies", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 20, no. 6, 1 December 2009 (2009-12-01), pages 685-691, XP026778879, ISSN: 0958-1669, DOI: 10.1016/J.COPBIO.2009.10.011 [retrieved on 2009-11-04]</text></B562><B562><text>HAMILTON ET AL: "Glycosylation engineering in yeast: the advent of fully humanized yeast", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 18, no. 5, 24 October 2007 (2007-10-24), pages 387-392, XP022350908, ISSN: 0958-1669, DOI: 10.1016/J.COPBIO.2007.09.001</text></B562><B562><text>BETENBAUGH M J ET AL: "Biosynthesis of human-type N-glycans in heterologous systems", CURRENT OPINION IN STRUCTURAL BIOLOGY, ELSEVIER LTD, GB, vol. 14, no. 5, 1 October 2004 (2004-10-01), pages 601-606, XP004590073, ISSN: 0959-440X, DOI: 10.1016/J.SBI.2004.09.001</text></B562><B562><text>JEFFERIS ROY: "Glycosylation as a strategy to improve antibody-based therapeutics", NATURE REVIEWS. DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, vol. 8, no. 3, 1 March 2009 (2009-03-01), pages 226-234, XP002600969, ISSN: 1474-1784, DOI: 10.1038/NRD2804</text></B562><B562><text>LIU H ET AL: "Heterogeneity of monoclonal antibodies", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 97, no. 7, 1 July 2008 (2008-07-01), pages 2426-2447, XP002530921, ISSN: 0022-3549, DOI: 10.1002/JPS.21180</text></B562><B562><text>MOORE GREGORY L ET AL: "Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions", MABS, LANDES BIOSCIENCE, US, vol. 2, no. 2, 1 March 2010 (2010-03-01), pages 181-189, XP009143498, ISSN: 1942-0862, DOI: 10.4161/MABS.2.2.11158 &amp; G L Moore ET AL: "Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions (Supplementary Information)", mAbs, 1 March 2010 (2010-03-01), pages 1-2, XP055045074, Retrieved from the Internet: URL:http://dx.doi.org/10.4161/mabs.2.2.111 58 [retrieved on 2012-11-21]</text></B562><B562><text>CHOWDHURY P S ET AL: "Tailor-made antibody therapeutics", METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 36, no. 1, 1 May 2005 (2005-05-01), pages 11-24, XP027216559, ISSN: 1046-2023 [retrieved on 2005-04-19]</text></B562><B562><text>FILPULA ET AL: "Antibody engineering and modification technologies", BIOMOLECULAR ENGINEERING, ELSEVIER, NEW YORK, NY, US, vol. 24, no. 2, 1 June 2007 (2007-06-01), pages 201-215, XP022081380, ISSN: 1389-0344, DOI: 10.1016/J.BIOENG.2007.03.004</text></B562><B562><text>ANTES ET AL: "Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function", JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES &amp; APPLICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 852, no. 1-2, 31 May 2007 (2007-05-31), pages 250-256, XP022099894, ISSN: 1570-0232, DOI: 10.1016/J.JCHROMB.2007.01.024</text></B562><B562><text>BRUNHOUSE R ET AL: "Isotypes of IgG: Comparison of the primary structures of three pairs of isotypes which differ in their ability to activate complement", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 16, no. 11, 1 November 1979 (1979-11-01), pages 907-917, XP023788873, ISSN: 0161-5890, DOI: 10.1016/0161-5890(79)90089-0 [retrieved on 1979-11-01]</text></B562></B560></B500><B600><B620EP><parent><cdoc><dnum><anum>17184944.1</anum></dnum><date>20170804</date></cdoc></parent></B620EP></B600><B700><B720><B721><snm>PARREN, Paul</snm><adr><str>Werdorperwaard 17</str><city>3984 PR Odijk</city><ctry>NL</ctry></adr></B721><B721><snm>VAN BERKEL, Patrick</snm><adr><str>Derde Westerparklaan 321</str><city>3544 NH Utrecht</city><ctry>NL</ctry></adr></B721><B721><snm>VAN DEN BREMER, Ewald</snm><adr><str>c/o Genmab B.V.
Yalelaan 60</str><city>3584 CM Utrecht</city><ctry>NL</ctry></adr></B721></B720><B730><B731><snm>Genmab A/S</snm><iid>101675037</iid><irf>P/0070-EP</irf><adr><str>Kalvebod Brygge 43</str><city>1560 Copenhagen V</city><ctry>DK</ctry></adr></B731></B730><B740><B741><snm>Genmab A/S</snm><iid>101354316</iid><adr><str>Kalvebod Brygge 43</str><city>1560 Copenhagen V</city><ctry>DK</ctry></adr></B741></B740></B700><B800><B840><ctry>AL</ctry><ctry>AT</ctry><ctry>BE</ctry><ctry>BG</ctry><ctry>CH</ctry><ctry>CY</ctry><ctry>CZ</ctry><ctry>DE</ctry><ctry>DK</ctry><ctry>EE</ctry><ctry>ES</ctry><ctry>FI</ctry><ctry>FR</ctry><ctry>GB</ctry><ctry>GR</ctry><ctry>HR</ctry><ctry>HU</ctry><ctry>IE</ctry><ctry>IS</ctry><ctry>IT</ctry><ctry>LI</ctry><ctry>LT</ctry><ctry>LU</ctry><ctry>LV</ctry><ctry>MC</ctry><ctry>MK</ctry><ctry>MT</ctry><ctry>NL</ctry><ctry>NO</ctry><ctry>PL</ctry><ctry>PT</ctry><ctry>RO</ctry><ctry>RS</ctry><ctry>SE</ctry><ctry>SI</ctry><ctry>SK</ctry><ctry>SM</ctry><ctry>TR</ctry></B840><B844EP><B845EP><ctry>BA</ctry><date>20140131</date></B845EP><B845EP><ctry>ME</ctry><date>20140131</date></B845EP></B844EP><B860><B861><dnum><anum>EP2012063338</anum></dnum><date>20120706</date></B861><B862>en</B862></B860><B870><B871><dnum><pnum>WO2013004841</pnum></dnum><date>20130110</date><bnum>201302</bnum></B871></B870><B880><date>20140514</date><bnum>201420</bnum></B880></B800></SDOBI>
</ep-patent-document>
